California Public Employees Retirement System Has $823,000 Stake in Omeros Corporation (OMER)

California Public Employees Retirement System decreased its position in Omeros Corporation (NASDAQ:OMER) by 4.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 54,400 shares of the biopharmaceutical company’s stock after selling 2,400 shares during the period. California Public Employees Retirement System owned 0.12% of Omeros Corporation worth $823,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in OMER. Russell Investments Group Ltd. acquired a new position in shares of Omeros Corporation during the first quarter worth approximately $292,000. American International Group Inc. boosted its position in shares of Omeros Corporation by 15.2% in the first quarter. American International Group Inc. now owns 24,521 shares of the biopharmaceutical company’s stock worth $371,000 after buying an additional 3,232 shares in the last quarter. Parametric Portfolio Associates LLC acquired a new position in shares of Omeros Corporation during the first quarter worth approximately $406,000. Sheaff Brock Investment Advisors LLC boosted its position in shares of Omeros Corporation by 21.7% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 28,000 shares of the biopharmaceutical company’s stock worth $423,000 after buying an additional 5,000 shares in the last quarter. Finally, Mesirow Financial Investment Management Equity Management boosted its position in shares of Omeros Corporation by 24.8% in the first quarter. Mesirow Financial Investment Management Equity Management now owns 35,000 shares of the biopharmaceutical company’s stock worth $530,000 after buying an additional 6,960 shares in the last quarter. Hedge funds and other institutional investors own 43.94% of the company’s stock.

Omeros Corporation (NASDAQ:OMER) traded up 0.44% on Wednesday, hitting $22.62. 250,766 shares of the stock were exchanged. Omeros Corporation has a 1-year low of $7.20 and a 1-year high of $27.09. The company has a 50-day moving average price of $21.41 and a 200 day moving average price of $16.46. The company’s market capitalization is $1.01 billion.

Omeros Corporation (NASDAQ:OMER) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.12. The firm had revenue of $17.15 million for the quarter, compared to analyst estimates of $14.63 million. The business’s revenue was up 71.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.32) EPS. Analysts anticipate that Omeros Corporation will post ($1.24) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/08/16/california-public-employees-retirement-system-has-823000-stake-in-omeros-corporation-omer.html.

OMER has been the subject of a number of analyst reports. Maxim Group set a $23.00 price target on shares of Omeros Corporation and gave the stock a “buy” rating in a research note on Monday, May 22nd. BidaskClub upgraded shares of Omeros Corporation from a “hold” rating to a “buy” rating in a research note on Sunday, June 18th. Cantor Fitzgerald set a $15.00 price target on shares of Omeros Corporation and gave the stock a “hold” rating in a research note on Tuesday, June 13th. ValuEngine upgraded shares of Omeros Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research upgraded shares of Omeros Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Omeros Corporation has a consensus rating of “Buy” and a consensus price target of $32.80.

In related news, VP Michael A. Jacobsen sold 12,000 shares of the stock in a transaction that occurred on Friday, June 16th. The shares were sold at an average price of $24.95, for a total transaction of $299,400.00. Following the sale, the vice president now owns 19,500 shares in the company, valued at approximately $486,525. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Michael A. Jacobsen sold 24,000 shares of the stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $21.20, for a total transaction of $508,800.00. Following the sale, the vice president now owns 2,650 shares in the company, valued at approximately $56,180. The disclosure for this sale can be found here. Company insiders own 13.60% of the company’s stock.

About Omeros Corporation

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)

What are top analysts saying about Omeros Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Omeros Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit